Isec Healthcare Ltd · SGX:40T
Isec Healthcare — 9M2018 Earnings Presentation
21 slides from Isec Healthcare's earnings presentation, Nov 5, 2018
Slide 1: Corporate Presentation – 9 months ended 30 September 2018
Corporate Presentation 9 months ended 30 September 2018 Page 0
Slide 2: Sponsor disclaimer
This presentation has been prepared by the Company and its contents have been reviewed by the Company’s sponsor, PrimePartners Corporate Finance Pte. Ltd. (the “Sponsor”), for compliance with the Singapore Exchange Securities Trading Limited (the “SGX-ST”) Listing Manual Section B: Rules of Catalist
Slide 3: Table of Content
Table of Content Business Overview Competitive Strengths of the Group Business Strategy and Expansion Plans Corporate Developments and Use of Proceeds 9 months Financial Highlights for the Period Ended 30 September 2018 Page 2
Slide 4: Business Overview
Business Overview Page 3
Slide 5: Business Overview
Business Overview • Specialised Health Services – Medical eye care service provider • ISEC is a comprehensive medical eye care service provider, with ambulatory surgical centres in Malaysia (Kuala Lumpur, Penang, Malacca & Sibu) and provides specialist medical ophthalmology services to Lee Hung Ming
Slide 6: Competitive Strengths of the Group
Competitive Strengths of the Group Page 5
Slide 7: Competitive Strengths of the Group
Competitive Strengths of the Group 1 Highly qualified and experienced specialist doctors 6 Business model aligns the 2 interests of our High quality and specialist doctors with comprehensive range of our Group and eye care services Shareholders 5 Ability to replicate our 3 Well positioned to busines
Slide 8: Business Strategy and Expansion Plans
Business Strategy And Expansion Plans Page 7
Slide 9: Our Business Strategies
Our Business Strategies To reach out to more patients in locations where we currently operate, as well as new locations such as major Growing the ISEC cities or locations in Peninsular Malaysia, East Malaysia and Brand and Singapore Expanding into To expand via setting up of subsidiaries, joint
Slide 10: Expansion Plans: Business expansion in the Asia Pacific region
Expansion Plans Business expansion in the Asia Pacific region (including Malaysia Malaysia & and Singapore) Singapore Target Countries Page 9
Slide 11: Corporate Developments and Use of Proceeds
Corporate Developments And Use of Proceeds Page 10
Slide 12: Corporate Developments: Joint Venture into ISEC Myanmar
Corporate Developments JOINT VENTURE INTO ISEC MYANMAR COMPANY LIMITED On 8 August 2018, the Company through its wholly owned subsidiary, ISEC Global Pte. Ltd. (“ISEC Global”) had incorporated a joint venture company in Myanmar (the “Joint Venture”) known as ISEC Myanmar Company Limited (“ISEC Myanm
Slide 13: Corporate Developments: Subscription of Shares in I Medical & Aesthetics
Corporate Developments SUBSCRIPTION OF SHARES IN I MEDICAL & AESTHETICS PTE. LTD. On 20 August 2018, the Company, through its wholly-owned subsidiary, JL Medical (Bukit Batok) Pte. Ltd., had completed a subscription of 250,000 ordinary shares in I Medical & Aesthetics Pte. Ltd. (“I Medical & Aesthet
Slide 14: Use of Proceeds
Use of Proceeds As at 5 November 2018 Amount allocated pursuant to reallocation of Use of proceeds Amount allocated unutilised listing Amount S$’000 expenses utilised Balance S$’000 S$’000 S$’000 Business expansion in Asia Pacific region (including Malaysia and 13,800 300 (12,921) (N1) 1,179 Singapo
Slide 15: 9 Months Financial Highlights
9 Months Financial Highlights for the Period Ended 30 September 2018 Page 14
Slide 16: Revenue
Revenue SGD’mil 9M2018 vs 9M2017 The increase in Group revenue was mainly attributable to increased patient visits from the Group’s specialised eye care services in Malaysia and Singapore. Page 15
Slide 17: Revenue – Malaysia
Revenue – Malaysia RM’mil SGD’mil 5.6% 11.2% Revenue from Malaysia operations in Ringgit Malaysia (“RM”) increased from RM64.4 million in 9M2017 to RM68.0 million in 9M2018, up 5.6% mainly due to increased number of patients visits. Singapore Dollar translated revenue from Malaysia operations in 9
Slide 18: EBITDA and Profit After Tax (PAT)
Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) and Profit After Tax (PAT) SGD’000 8.5% 7.5% EBITDA was S$9.2 million in 9M2018 as compared to S$8.5 million in 9M2017, an increase of S$0.7 million mainly due to increased patient visits from the Group’s specialised eye care se
Slide 19: Cash Position
Cash Position Total cash and cash equivalents Unutilised IPO proceeds Cash balances SGD’mil Total cash and cash equivalents as at 30 September 2018 was S$23.7 million. No debt. Cash balances (excluding unutilised IPO proceeds) decreased from S$23.3 million as at 31 December 2017 to S$22.5 millio
Slide 20: Statement of Financial Position
Statement of Financial Position S$’000 30 September 31 December 2018 2017 Key Assets Plant and equipment 3,594 3,894 Intangible assets 38,352^ 38,766^ Trade and other receivables 2,815 2,505 Cash and cash equivalents 23,658 24,824 Key Liabilities Trade and other payables 3,327 3,475 Equity Total equ
Slide 21: Thank You
Thank You Page 20